Astellas Pharma, Inc.

Astellas Pharma, Inc.

Astellas Pharma, Inc.

Overview
Date Founded

1939

Headquarters

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, JPN

Type of Company

Public

Employees (Worldwide)

16.6K

Industries

Pharmaceuticals
Hospitals & Patient Services
Wholesale: Consumer Non-Durables/Sundries
Medical Products & Equipment
Medical Support Services
Biotechnology

Company Description

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

Contact Data
Trying to get in touch with decision makers at Astellas Pharma, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Director, Communications & Corporate Citizenship

Senior Managing Executive Officer & General Manager-Asia

President, Development

President & Head of Development

Senior Vice President & Head of Medical Affairs, Americas

Senior Executive Officer, Director of External Affairs

Senior Vice President & Oncology Therapeutic Area Head

Vice President of Medical Science for Hematology, Oncology Therapeutic Area

Vice President, Rx+ Medical & Development Head

Board of Directors

Former President, Representative Director at Astellas Pharma, Inc.

President & Representative Director at SU Consultant Co., Ltd.

President & Chief Executive Officer at Astellas Pharma, Inc.

Professional at Astellas Pharma, Inc.

Professional at Astellas Pharma, Inc.

Professional at Astellas Pharma, Inc.

Corporate Adviser at Marubeni Corporation

Former Vice President, Clinical & Research Quality Assurance at Astellas Pharma, Inc.

Director at Astellas Pharma, Inc.

Independent Outside Director at Astellas Pharma, Inc.

Paths to Astellas Pharma, Inc.
Potential Connections via
Relationship Science
You
Astellas Pharma, Inc.
Owners & Shareholders
Details Hidden

NAM-J's investment philosophy has core elements including: active management focusing on fundamental research; a team approach; and thorough risk/return assessment. They offer a broad range of equity strategies, including core, value, and growth. The investment approach of the core strategy combines a bottom-up, relative value approach with rigorous fundamental research on individual stocks and a top-down overlay. The investment process is designed to add value in all market conditions over a medium- to long-term horizon. For value, they use bottom-up approach without sector constraints where the quality of stock selection is paramount. The investment process is based on a combination of rigorous quantitative screening based on valuation factors with liquidity consideration and qualitative analysis on firms' fundamentals. The growth strategy focuses on ROE level and sustainability and fundamental strength. In conducting NAM-J's investment decisions, they utilize a broad spectrum of information, including financial publications, third-party research materials, annual reports, prospectuses, regulatory filings, company press releases, corporate rating services, inspections of corporate activities and meetings with management of various companies.

Details Hidden

SMTAM's fund managers of their respective investment departments implement investments in line with the investment plans and manage funds. The general managers of their respective investment departments check the status of investment implementations carried out by the fund managers thereof. Execution of buy or sell orders is carried out by traders at the Trading Department which is independent of the respective investment departments, based on execution instructions for investments from the respective investment departments. The firm leverages the strengths, operational structure, know-how and network of their parent company to manage assets, utilizing bottom-up and top-down quantitative investment styles to make investments through their range of funds.

Details Hidden

DAM conducts in-house research and has a strong global research network. Their investment management philosophy is based on a mid-to-long-term perspective in which they try to identify hidden values which are not yet fully recognized in the market. The firm takes a balanced approach emphasizing both fundamental and quantitative analysis. DAM's basic assumption is that the market is not fully efficient and they employ a coherent investment process through organizational support at each phase of their 'Plan', 'Do' and 'Review' policy. They pursue stable excess mid-to long-term returns through suitable risk control, which they separate from investment management to ensure that the risk control system adequately monitors their investment process. The firm's research team analysts and portfolio managers discuss, evaluate and communicate market events and investment opinions, seeking to maximize portfolio performance. Company visits are important components of their bottom-up research process and are a primary source for their fundamental analysis.

Recent Transactions
Details Hidden

CMIC Holdings Co., Ltd., CMIC CMO Co., Ltd. purchase Astellas Pharma Tech Co. Ltd. /Nishine Plant Bus from Astellas Pharma, Inc.

Details Hidden

Société Régionale d'Investissement de Wallonie SA, BNP Paribas Fortis Private Equity Belgium NV, SFPI-FPIM (Private Equity), Fund+, Newton Biocapital Partners SPRL, Epics Therapeutics SA purchase Ogeda SA from Astellas Pharma, Inc.

Details Hidden

Astellas Pharma, Inc. purchases Potenza Therapeutics, Inc. from Mpm Capital LLC, InterWest Partners, LLC, Astellas Venture Management LLC

Transaction Advisors
Legal Advisor

Advised onAstellas Pharma, Inc. purchases OSI Pharmaceuticals, Inc.

Legal Advisor

Advised onSociété Régionale d'Investissement de Wallonie SA, BNP Paribas Fortis Private Equity Belgium NV, SFPI-FPIM (Private Equity), Fund+, Newton Biocapital Partners SPRL, Epics Therapeutics SA purchase Ogeda SA from Astellas Pharma, Inc.

Investment Advisor

Advised onAstellas Pharma, Inc. purchases OSI Pharmaceuticals, Inc.

Legal Advisor

Advised onAstellas Pharma, Inc. purchases GANYMED Pharmaceuticals AG from Future Capital, MIG Verwaltungs AG, ATS Beteiligungsverwaltung GmbH

Legal Advisor

Advised onAstellas Pharma, Inc., Astellas Pharma US, Inc. purchase Agensys, Inc.

Legal Advisor

Advised onAvara Pharmaceutical Services, Inc., Avara Norman Pharmaceutical Services, Inc. purchase Astellas Pharma Technologies, Inc. from Astellas Pharma, Inc.

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Legal Advisor

Partner at Kirkland & Ellis LLP

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Lupin Ltd. engages in the manufacture of pharmaceutical products. Its offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Key Stats and Financials As of 2018
Market Capitalization
$3.16T
Total Enterprise Value
$2.95T
Earnings Per Share
$81.11
Revenue
$1.3T
Net Profit
$165B
Total Equity
$1.27T
EBITDAMargin
25.85%
EBITDA
$336B
Enterprise Value Sales
2.27x
Enterprise Value EBITDAOperating
8.78x
TEVNet Income
17.91x
Debt TEV
0x
Total Debt
$1.35B
Three Year Compounded Annual Growth Rate Of Revenue
1.4%
Five Year Compounded Annual Growth Rate Of Revenue
5.27%
Non-Profit Donations & Grants
Investments
Details Hidden

Oncolys BioPharma, Inc. engages in the research and development of oncolytic viruses, drugs for serious infectious diseases, molecular targeted anti-cancer drugs, and tumor diagnostic agents. It also offers consulting services with regard to the research and development of biotechnology drugs. It operates through the following segments: Pharmaceutical and Diagnostics. The Pharmaceutical segments deals with the research, development, manufacture and sale of pharmaceutical products. The Diagnostics segment consists of the research, development, manufacture and sale of test drug and equipment, as well as the provision of inspection services. The company was founded by Yasuo Urata on March 18, 2004 and is headquartered in Tokyo, Japan.

Details Hidden

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

Details Hidden

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Investors
Details Hidden

Co-Founder at Longitude Capital Management Co. LLC

Details Hidden

Managing Member at VHCP Management LLC

Suppliers
Ironwood Pharmaceuticals, Inc. Pharmaceuticals | Cambridge, Massachusetts

At Ironwood, we seek to transform knowledge into medicines that make a difference for patients. Patients shape our business. They influence our drugmaking process, helping us to understand and address their unmet medical needs, whether we’re creating a new medicine or tackling the equally challenging task of delivering that medicine to people around the world. Our employees shape our success. Since our founding in 1998, each of our employees has held shares in the company. Being owners of Ironwood means we are all careful stewards of our resources: we take a data-driven approach in which we celebrate definitive answers – whether those answers support holding steady or changing course – and we challenge every program to earn its way forward. Our discovery and development processes have generated a product that’s approved in the United States and in the European Union, as well as a robust pipeline. As we continue to do drugmaking well, we hope to inspire the support of our shareholders and earn the right to do it again – building an enduring pharmaceutical company that understands and addresses people’s needs.

Gilead Sciences, Inc. Hospitals & Patient Services | FOSTER CITY, CA

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Medivation, Inc. Pharmaceuticals | SAN FRANCISCO, CA

Medivation blends a unique business model with an expert team to bring promising medical technologies from the lab bench to the patient bedside. Our enzalutamide (formerly MDV3100) clinical development program addresses a large market with significant unmet medical needs. Medivation was founded by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical, biotechnology and medical device industries. We founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Through our extensive network of contacts with top-flight scientists and research institutions, we acquire early-development stage pharmaceuticals and medical devices that have promising clinical, intellectual property and commercial prospects. Using the extensive development experience and expertise of our core team, supplemented by expert consultants in relevant functions, we identify and execute the strategic pathway that will allow the most rapid, efficient and effective development. ?Our business strategy is straightforward: Build a portfolio of four to six product candidates that have the potential to be in clinical development within 12 to 18 months after acquisition; clinical studies and commercialization or, depending on the indication, conduct those activities internally. Develop those product candidates as rapidly and efficiently as possible; and Consider partnering or selling successful programs to large pharmaceutical, biotechnology or medical device companies for late-stage clinical studies and commercialization or, depending upon the indication, conduct those activities internally. Our enzalutamide development program addresses a large market with significant unmet medical needs.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Astellas Pharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Astellas Pharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Astellas Pharma, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/astellas-pharma-inc-590543
  • https://relationshipscience.com/organization/astellas-pharma-inc-590543